AngioDynamics Past Earnings Performance
Past criteria checks 0/6
AngioDynamics's earnings have been declining at an average annual rate of -14.4%, while the Medical Equipment industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 4.3% per year.
Key information
-14.4%
Earnings growth rate
-12.6%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 4.3% |
| Return on equity | -123.6% |
| Net Margin | -83.0% |
| Last Earnings Update | 31 Aug 2024 |
Recent past performance updates
Recent updates
AngioDynamics, Inc. (NASDAQ:ANGO) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Jul 19
Improved Revenues Required Before AngioDynamics, Inc. (NASDAQ:ANGO) Stock's 26% Jump Looks Justified
Jul 18AngioDynamics: A Story To Monitor
May 14A Leaner AngioDynamics Is A High-Risk Execution-Driven Story
Apr 09AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry
Apr 06AngioDynamics: Restructuring Initiative May Not Go Far Enough
Jan 14AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Oct 12AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt
Mar 31AngioDynamics Non-GAAP EPS of -$0.06 misses by $0.04, revenue of $81.5M misses by $1.93M, reaffirms FY guidance
Oct 06AngioDynamics: Lack Of Upside Capture Remains, Continue To Hold
Sep 29Is AngioDynamics (NASDAQ:ANGO) Using Debt In A Risky Way?
Sep 02AngioDynamics Non-GAAP EPS of $0.01 in-line, revenue of $87M beats by $4.09M
Jul 12Revenue & Expenses Breakdown
How AngioDynamics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 24 | 293 | -243 | 143 | 30 |
| 31 May 24 | 304 | -184 | 144 | 31 |
| 29 Feb 24 | 324 | -192 | 146 | 32 |
| 30 Nov 23 | 330 | -14 | 144 | 31 |
| 31 Aug 23 | 336 | 6 | 146 | 29 |
| 31 May 23 | 339 | -52 | 144 | 30 |
| 28 Feb 23 | 335 | -37 | 146 | 30 |
| 30 Nov 22 | 328 | -33 | 144 | 31 |
| 31 Aug 22 | 321 | -33 | 140 | 32 |
| 31 May 22 | 316 | -27 | 134 | 30 |
| 28 Feb 22 | 306 | -40 | 133 | 32 |
| 30 Nov 21 | 303 | -38 | 130 | 33 |
| 31 Aug 21 | 298 | -34 | 126 | 34 |
| 31 May 21 | 291 | -32 | 117 | 36 |
| 28 Feb 21 | 273 | -169 | 112 | 34 |
| 30 Nov 20 | 271 | -171 | 114 | 33 |
| 31 Aug 20 | 268 | -170 | 116 | 32 |
| 31 May 20 | 264 | -167 | 117 | 30 |
| 29 Feb 20 | 277 | -7 | 120 | 29 |
| 30 Nov 19 | 273 | -6 | 116 | 28 |
| 31 Aug 19 | 273 | -7 | 113 | 27 |
| 31 May 19 | 271 | -11 | 112 | 28 |
| 28 Feb 19 | 205 | -34 | 107 | 27 |
| 30 Nov 18 | 223 | -16 | 106 | 26 |
| 31 Aug 18 | 240 | -12 | 103 | 25 |
| 31 May 18 | 262 | -6 | 104 | 24 |
| 28 Feb 18 | 343 | 1 | 108 | 25 |
| 30 Nov 17 | 345 | -10 | 108 | 25 |
| 31 Aug 17 | 347 | 4 | 109 | 25 |
| 31 May 17 | 270 | -7 | 106 | 24 |
| 28 Feb 17 | 356 | -25 | 109 | 26 |
| 30 Nov 16 | 358 | -27 | 111 | 25 |
| 31 Aug 16 | 357 | -42 | 113 | 26 |
| 31 May 16 | 351 | -44 | 114 | 25 |
| 29 Feb 16 | 347 | -1 | 116 | 25 |
| 30 Nov 15 | 346 | -6 | 115 | 26 |
| 31 Aug 15 | 349 | -5 | 114 | 26 |
| 31 May 15 | 352 | -3 | 112 | 27 |
| 28 Feb 15 | 356 | -4 | 111 | 26 |
| 30 Nov 14 | 358 | 5 | 112 | 27 |
| 31 Aug 14 | 354 | 4 | 111 | 27 |
| 31 May 14 | 351 | 2 | 112 | 28 |
| 28 Feb 14 | 346 | 2 | 108 | 27 |
| 30 Nov 13 | 340 | -3 | 105 | 26 |
Quality Earnings: ANGO is currently unprofitable.
Growing Profit Margin: ANGO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ANGO is unprofitable, and losses have increased over the past 5 years at a rate of 14.4% per year.
Accelerating Growth: Unable to compare ANGO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANGO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.7%).
Return on Equity
High ROE: ANGO has a negative Return on Equity (-123.63%), as it is currently unprofitable.